Friday 14 February 2020

Gamma-Linolenic Acid, A Potential Treatment of Dermatitis in Vitro

By Kyle J. Norton

Dermatitis is condition associated skin irritation that involves itchy, dry skin or a rash on swollen, reddened skin.

Contact dermatitis is a skin condition with symptoms of a red, itchy rash caused by direct contact with a substance or an immune overreaction against contact allergens.

Many chemicals and nonchemicals substances have been found to induce abnormal reactions, including cosmetics, fragrances, jewelry, and plants.

Most cases of contact dermatitis are nonlife-threatening, however, the condition can induce certain discomforts, particularly in people with an allergic reaction to other conditions.

Contact dermatitis can be healed within a week or 2. The condition can be preventable if the cause is identified.

Besides the common symptoms of a red, itchy rash on the skin, some people may experience more serious symptoms including crusting swelling, burning or tenderness skin.

Atopic dermatitis or eczema is an inflammatory condition associated with red and itchy skin.

Most cases of atopic dermatitis are found in children. However, adults may also get it too. Skin irritation is found more often in children compared to adults.

The causes of atopic dermatitis are unknown. Some researchers suggested that certain risk factors such as genetic preposition and abnormal function of the immune system and environment conditions may be involved in the development of the disease.

Conventionally, dermatitis is treated by
* Steroid creams or ointments for soothing the rash.

* Oral medications such as oral corticosteroids for reducing inflammation, antihistamines to relieve itching or antibiotics to fight a bacterial infection.

Gamma-linolenic acid is a phytochemical in the group of Omega-3, 6,9 fatty acids, belongings to the class of Lipids, found abundantly in evening primrose, borage, blackcurrant, etc.

On finding a potential plant that processes anti-skin disease activity, researchers examined the effect of Dihomo-γ-linolenic acid (DGLA, C20: 3n-6), an anti-inflammatory agent on dermatitis.

According to the results of the analysis of yeast Saccharomyces cerevisiae strain as a DGLA synthesis
* Oral intake of this yeast significantly suppressed inflammatory reactions, compared to no such suppression that was observed by the intake of 25 times the amount of purified DGLA.

* Yeast Saccharomyces cerevisiae strain as a DGLA synthesis was considered to be a simple and efficient way to suppress inflammation.

* Furthermore, the synthesis compound also was effective against allergic contact dermatitis (ACD).

Taken altogether, -γ-linolenic acid may be considered a remedy for the prevention and treatment of dermatitis, pending to the confirmation of the larger sample size and multicenter human study.


Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight

How To Get Rid Of Eye Floaters 
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally 

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How-To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

Back to Kyle J. Norton Homepage http://kylejnorton.blogspot.ca


Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)

Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bioscience, ISSN 0975-6299.

Sources
(1) Oral administration of whole dihomo-γ-linolenic acid-producing yeast suppresses allergic contact dermatitis in mice by Watanabe N1, Teradu S1, Ohtani M1, Uemura H. (PubMed)

No comments:

Post a Comment